Ex Vivo Drug Response Testing in Lung Adenocarcinoma with Malignant Pleural Effusions
Official title: Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma
Run by Sheba Medical Center · NCT07636252 · Data updated 2026-11-12
This study tests whether the way cancer cells from pleural effusions respond to drugs outside the body can predict how patients will respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Sheba Medical Center Government |
| Locations | 1 site (Ramat Gan, Israel) |
| Status | Recruiting |
| Started | June 14, 2023 |
| Main results expected | December 1, 2028 |
| Study ends | January 1, 2030 |
| Registry record updated | June 23, 2026 |
| Trial ID | NCT07636252 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Patients with lung cancer or suspected lung cancer who have a pleural effusion requiring drainage and consent to donate the effusion for testing.
✕Probably not a fit
Patients whose tumor cells do not show a clear drug response pattern or who do not receive subsequent therapy matching the ex vivo results may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study uses tumor cells collected from malignant pleural effusions of patients with lung adenocarcinoma. After enriching tumor cells, researchers expose them to a panel of FDA-approved targeted therapies and measure viability after 72 hours to identify the most effective drugs at low concentrations. They compare ex vivo drug responses with patients’ driver mutations and clinical outcomes to see if the test can predict treatment responses. The goal is to develop a rapid, functional drug sensitivity platform that complements genetic sequencing in guiding therapy choices. The study is conducted at Sheba Medical Center in Israel and uses non-interventional methods.
Why it matters
Potential benefit: If successful, the test could help tailor treatments by identifying effective drugs for individual patients based on their tumor cells.
How similar studies have gone: Other studies have explored functional drug sensitivity testing, but this approach using malignant pleural effusions and rapid 72-hour readout is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing. * Patient's written informed consent present. * Ability to understand the nature of the trial and the trial related procedures and to comply with them. Exclusion Criteria: * negative cytology for malignancy in the last 6 months
Where it's running
-
Sheba Medical Center
Ramat Gan, Israel, Israel Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Feasibility of a disposable flexible bronchoscope for thoracoscopy compared with a semi-rigid pleuroscope in pleural effusion
This study tests whether a single-use flexible bronchoscope can be used safely and effectively for medical thoracoscopy in patients with pleural effusion, compared with the standard semi-rigid pleuroscope.
-
DBC-664 in adults with solid tumors
A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.
-
Vortioxetine for cognitive problems in ALK/ROS1-positive NSCLC treated with lorlatinib
This observational study tests whether vortioxetine can help with cognitive and neurological side effects in adults with ALK/ROS1-positive NSCLC who are taking lorlatinib.
-
Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain
This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.
-
7-day low-carb, high-fat (ketogenic) diet to improve FDG PET/CT detection of lepidic lung adenocarcinoma
This trial will test whether a personalized 7-day ketogenic (low-carb, high-fat) diet before an FDG PET/CT can improve detection of lepidic-predominant lung adenocarcinoma in adults with a suspicious lung nodule or confirmed diagnosis.
-
Partial high-dose tumor irradiation combined with immunotherapy for unresectable lung adenocarcinoma
This trial will try giving very high-dose radiation to the central part of large, unresectable lung adenocarcinomas while preserving the surrounding immune tissue and pairing that with an immune checkpoint drug for patients who have no remaining standard treatment options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.